PROMORE PHARMA
leading-edge medical innovation

Interim report, Jan-Jun 2021

- **Adjustment of the company's strategy – ensereptide is focused on scar prevention**
- **Production agreement for hyaluronic acid signed with Italian firm Fidia**
- **Patent granted in the US regarding prevention of skin scarring**
- **A fully subscribed new share issue yielded net proceeds of SEK 45 million**



Promore Pharma AB (publ)

Interim report January - June 2021

April to June

- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -7.9 (-6.5), corresponding to earnings per share of SEK -0.22 (-0.18)
- Cash flow from operating activities amounted to MSEK -54.1 (-6.0)
- Cash amounted to MSEK 13.1 (39.9). The funds from the new share issue was added to the company after the end of the period

January to June

- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -15.0 (-13.6), corresponding to earnings per share of SEK -0.41 (-0.37)
- Cash flow from operating activities amounted to MSEK -60.9 (-21.0)

Significant events during January – June

- In January, the company entered an agreement with Erik Penser Bank AB regarding services as Certified Adviser. Erik Penser Bank took over as Certified Adviser on 25 January 2021.
- In March, Promore Pharma decided on an adjustment of the company's strategy. The development of the drug candidate ensereptide (PXL01) will be focused on scar prevention in connection with surgery.
- In March, warrants corresponding to a dilution of 3.0% of the number of outstanding shares were deregistered.
- In April, an important milestone was achieved when the company signed an agreement with the Italian company, Fidia Farmaceutici S.p.A,. for the production of GMP certified hyaluronic acid.
- In May, a fully guaranteed new share issue of approximately SEK 48 million was announced for the purpose of implementing the revised strategy of the company.
- In May, it was also announced that the company received a granted patent in the United States for the use of the peptide ensereptide (PXL01) for prevention of skin scarring.
- In June, the company announced that the new issue had been concluded, yielding a net SEK 45.0 million.
- Hans-Peter Ostler was elected new member of the board.

Events after the reporting period

- No significant events after the reporting period.

"We are very pleased with the response that we received in connection with the capital raise in the spring. Both existing and new capital-strong shareholders have shown confidence in both the company and the re-prioritization of the ensereptide program that has been directed towards the scarring market."

Jonas Ekblom, President and CEO of Promore Pharma

Financial overview for the Company

Amounts in MSEK	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020
Net sales	-	-	-	-
Operating loss	-7,8	-6,7	-14,9	-14,0
Profit/Loss for the period	-7,9	-6,5	-15,0	-13,6
Earnings per share, SEK	-0,22	-0,18	-0,41	-0,37
Cash flow from operating activities	-54,1	-6,0	-60,9	-21,0
Cash and cash equivalents at the end of the period	13,1	39,9	13,1	39,9

Promore Pharma in brief:

Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive wound care. Today, the company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.

Comments from the CEO

During the second quarter of the year, four essential milestones were achieved: (i) the completion of a capital raise which brought about SEK 45 million after transaction costs, (ii) the approval of a patent in the United States regarding ensereptide for prevention of scarring, (iii) signing a substantial manufacturing agreement with Fidia Farmaceutici S.p.A, as well as (iv) the initiation of the manufacturing of investigational product for the company's upcoming clinical trial of ensereptide for prevention of scars on the skin.

We are very pleased with the response that we received in connection with the capital raise in the spring. Both existing and new capital-strong shareholders have shown confidence in both the company and the re-prioritization of the ensereptide program that has been directed towards the scarring market. The capital increase enables several value-generating steps in Promore Pharma, and we look forward to initiating studies and further development efforts during the current and next year.

Within the ensereptide program, the company has now redirected the focus from hand surgery to develop a product to prevent skin scarring. Through this change, we will be able to address a significantly much larger market. The global market for products intended to prevent or treat scars on the skin is estimated at more than USD 25 billion. Today, there are no pharmaceutical products for prevention of scarring. The work has begun to manufacture an investigational product for the planned Phase II study, PHSU05, concerning the prevention of scarring on the skin. Our goal is to be able to start recruitment into this clinical trial during the first quarter of 2022. We are very satisfied that we could sign an agreement with Fidia Farmaceutici in April for the production of GMP-certified hyaluronic acid which constitutes an important raw material in the ensereptide product.

Within our project against chronic wounds (ropocamptide, LL-37), we have started compiling a scientific publication of the clinical study that was completed in Q4 2020 which showed statistically significant improvement in the healing of wounds greater than 10 cm^2. In addition, we are carrying out a comprehensive third-party review of the project to support the development strategy in the project. We have also begun some technical development aimed at product improvement. Whether the company performs future clinical studies on its own or with strategic partners, the development of a more user-friendly product will be important both in the clinical study environment and when the product reaches the market.

In parallel with this work, we also search for the possibility of strategic partnerships and alliances. There are several reasons why Promore Pharma sees a collaboration with a fully integrated company as an advantageous path forward to maximize the potential of the ropocamptide program, among other things for the execution of final clinical studies and also because the future commercialization of ropocamptide will require financial resources, knowledge and human resources that only larger pharmaceutical companies possess.

Promore Pharma has so far only been marginally affected by COVID-19. The HEAL LL-37 trial, that was completed in 2020 could be performed largely as planned, and since we are limiting the focus of ensereptide to scarring in skin, the planned Phase IIa study on that indication can be carried out with only marginal adjustments.

At the Annual General Meeting on 27 May 2021, Hans-Peter Ostler was elected as a new member of the company's board. Hans-Peter is, among other things, chairman of the board of Oblique Therapeutics and board member of Alligator Biosciences and Inorbit TX. On behalf of our company and network, I wish to extend a welcome to Hans-Peter, as well as a number of new shareholders who participated in our new share issue in June, to Promore Pharma and the exciting journey we have ahead of us.

Solna, August 24, 2021

Jonas Ekblom
President & CEO

Skin scarring

The underlying cause of scarring is similar in different clinical contexts such as scarring of the skin or adverse permanent adhesions of tissues that should normally be separated. It is a well-known fact that increased inflammation and fibrin formation after surgery are two key mechanisms that strongly contribute to scarring. Ensereptide is a unique molecule, as the peptide affects both of these key mechanisms.

Scarring on the skin can have both physical and psychological consequences, from reduced mobility and function to emotional trauma. Despite an extensive medical need and a clear demand, there are currently no pharmaceutical products on the market to prevent scarring on the skin.

Conducted clinical studies

Ensereptide has undergone a randomized, double-blind, Phase IIb study in 138 patients with flexor injury in the hand, where efficacy and safety were compared between PXL01 mixed with highly viscous hyaluronic acid and placebo for 12 months. At all times after surgery, the mobility of the injured finger improved for patients in the PXL01 group compared to the placebo group.

Other applications

There is a growing need and interest in in novel anti-adhesive therapies, and there are a significant number of surgical procedures that can result in undesirable adhesions. Besides hand injury, ruptures of the hamstring are common sports injuries, which sometimes carry the risk of adhesions that limit mobility. Also, surgical treatment of disc herniation can cause epidural fibrosis (scars) and it is considered a common reason why surgical treatment of disc herniation does not lead to a successful result. In addition, it is well documented that adhesions are common in orthopedic surgery, such as insertion of synthetic knee joints, and in surgical procedures in the thyroid, eye and abdomen.

Incidence of scarring

Scarring usually occurs during most surgeries, such as plastic surgery and caesarean sections, and this seems to occur regardless of how the surgical wound is closed. Severe skin scars can also occur after burn injuries. Promore Pharma has shown that PXL01 has relevant pharmacological properties to prevent dermal scarring.

The World Health Organization (WHO) estimates that the number of surgeries performed in the world exceeds 300 million annually. An estimated 8-10% of these procedures would likely justify the use of a future ensereptide product to prevent or limit the appearance of disfiguring scars. The number of invasive plastic surgeries amounts to over 10 million annually worldwide. It is also likely that a large proportion of women undergoing caesarean section would require a drug that prevents scarring. The number of caesarean sections in the USA and the EU amounts to about 2.5 million per year.

Global market for scar treatment

There is a significant demand for effective treatment that prevents scarring and a variety of products have been launched on the market, such as oils, creams, gels, dressings, and sprays. The global market for these products is estimated to amount to almost USD 25 billion in annual sales in 2021 and is expected to grow by an average of 10-11 percent per year in the coming years. Market growth is driven by an increasing number of surgical procedures, increased patient awareness, and because of the launch of new products that require significant capital investments, such as laser treatment.

Despite an extensive medical need, there are currently no pharmaceutical products on the market to prevent dermal scarring. The company estimates that ensereptide would have an addressable market of approximately USD 10 billion annually.

Overview of activities

Promore Pharma is a biopharmaceutical company that develops peptide-based product candidates aimed at the bioactive wound care market. Ensereptide (PXL01) is aimed at prevention of post-surgical adhesions and scars and is being prepared for clinical Phase III studies on patients undergoing tendon repair surgery of the hand. Ropocamptide (LL-37) has recently passed clinical Phase IIb trial on patients with venous leg ulcers.

Promore Pharma's product candidates are based on innate peptides, which are a part of the human defense and healing system and have a strong safety profile since they are quickly degraded in the blood stream and are therefore unlikely to contribute to severe systemic adverse events. This is supported by the results from prior clinical studies, where both ensereptide and ropocamptide showed strong tolerability and safety as well as efficacy. The product candidates are protected by several international patent families offering protection until 2030 and longer. The patents provide protection in several dimensions, such as therapeutic use, formulation, and dosage ranges.

Promore Pharma's product candidates represent first-in-category therapeutics for several patient groups, segments where patients experience pain, reduced mobility, and lowered quality-of-life. When Promore Pharma's product candidates in clinical development receive market authorization and are established as treatment for chronic wounds and for preventing adhesions and scars, it would mean shorter treatment times for patients and lower costs for society.

Promore Pharma is a small and cost-effective company without its own laboratories or research facilities, using a network of high-quality contract research organizations and contract manufacturing organizations. The company has experienced advisors in all critical aspects of the strategic planning process, including product development, regulatory affairs, design, and execution of clinical trials. Promore Pharma's overall strategy is to take the product candidates through clinical development to market authorization or to a point when a license agreement, alternatively a commercial deal with a larger pharmaceutical company with global presence, can be realized. Such transactions may include out-partnering/licensing, strategic partnerships, joint ventures, or asset sales.

About ensereptide (PXL01)

Ensereptide is derived from a human anti-bacterial protein (lactoferrin), which is part of the innate immune system. This protein and its peptide fragments have several modes of action, including immunomodulation and enhancement of fibrinolytic activity. It is well established that inflammation and fibrin formation after surgery or trauma are two pivotal mechanisms that strongly contribute to scar formation.

Ensereptide is aimed for local administration, and the development of the product is focused at preventing different kinds of scarring after surgery. In a Phase II clinical study that has been completed by the company in several countries of the European Union (EU), it has been demonstrated that ensereptide is efficacious and safe. Promore Pharma is preparing a clinical Phase II trial in EU to explore the efficacy of the product for prevention of skin scarring. The study is planned to be initiated in the beginning of 2022.

Every year, more than 300 million surgical procedures are performed worldwide, and a proportion of these procedures result in disfiguring skin scars, for example after plastic and trauma surgery. Today, there are no drug products for prevention skin scarring after surgery. The addressable market is estimated to exceed SEK 100 billion. In other types of surgical procedures, there is a risk for occurrence of internal scars, which can cause adhesions (unfavorable attachments of tissues). This is a major medical problem, for example after surgical repair of injured tendons in the hand.

About ropocamptide (LL-37)

Ropocamptide is based on a human antimicrobial peptide, which stimulates several processes in wound healing. In a clinical Phase IIa study conducted by the company in patients with venous leg ulcers (VLUs), ropocamptide showed, in the most effective dose, an increase in healing rate of relative wound area reduction of close to 70% after one month's treatment, suggesting a significantly higher efficacy than what has been reported for any other treatment in chronic wounds. No serious adverse events that were deemed to be caused by the investigational product occurred in the trial. The product candidate can be easily combined with the standard wound care treatments and given by a nurse or the patient.

The development of ropocamptide is initially focused on venous leg ulcers and the company has recently concluded a clinical Phase IIb study (HEAL LL-37) on patients with VLUs in Europe. VLUs constitute the largest category of all chronic, or hard-to-heal, ulcers and represent significant challenges to patients and healthcare systems since they are frequent, costly to manage, recurring, and may persist for months or years.

The development of ropocamptide focuses initially on VLUs but the company sees good potential in also developing ropocamptide for diabetic foot ulcers.

Significant events during January – June 2021

Change of Certified Adviser to Erik Penser Bank AB
In January, Promore Pharma AB entered into an agreement with Erik Penser Bank AB regarding the Certified Adviser service. Erik Penser Bank assumed the role on 25 January 2021. Until then, Redeye AB acted as Certified Adviser for the company.

Update of strategy and focus on scar prevention
In March, Promore Pharma's board decided to adjust the company's strategy. The development of the drug candidate ensereptide (PXL01) will focus on scar prevention in connection with surgery. The decision is based on a strong and improved patent situation in the USA and that a robust production process has been ensured. The changed strategic priorities mean that the capital requirement for the company is considerably reduced and at the same time ensereptide can address a significantly larger market than before.

Deregistration of warrants
In March, Promore Pharma announced that the company has had 72,755 warrants deregistered, corresponding to a dilution of 3.0% in programs 3-7 issued to Technomark Group USA LLC and Kentron Biotechnology Pvt Ltd. The warrants were issued in 2016 as part of the remuneration for planned CRO services in the clinical trial PHSU03. There are 54,599 warrants remaining related to programs 1, 2 and 8, respectively.

Agreement signed on production of hyaluronic acid with Italian manufacturer Fidia
In April, Promore Pharma AB and Fidia Farmaceutici S.p.A. ("Fidia") signed an agreement for the production of hyaluronic acid, which is one of the components of Promore Pharma's investigational drug ensereptide. Fidia is a world-leading manufacturer of pharma grade hyaluronic acid, and the agreement will make it possible for Promore Pharma to procure raw material of optimal quality at the required future scale. Ensereptide is being developed as a treatment to prevent skin scarring and post-surgical adhesions.

Intention to carry out a fully secured rights issue in order to implement the new strategy
In May, the Board of Promore Pharma AB, subject to the approval by an Extra General Meeting held on 27 May 2021, resolved to carry out a rights issue with preferential rights for the Company's existing shareholders of SEK 48.6 million before transaction costs for the purpose of implementing the new strategy that was communicated on 31 March 2021. The subscription price amounts to SEK 2.00 per new share. Existing shareholders and new investors have signed subscription commitments and undertakings to subscribe via acceded subscription rights corresponding to an amount of SEK 31.0 million. In addition, the Rights Issue is fully secured through underwritings. Through the Rights Issue, the planned Phase II study for ensereptide (PXL01) and the technical development of the administration form for ropocamptide (LL-37) will be fully financed.

Patent granted in the US regarding skin scarring
In May, Promore Pharma announced that the company had received a granted patent in the US for the use of the candidate drug ensereptide (PXL01) to prevent the formation of scarring on the skin.

Outcome in the new issue
In June it was announced that the company's rights issue with preferential rights for the shareholders ended on 17 June 2021. The subscription breakdown show that 89.2 percent was subscribed with and without the exercise of subscription rights. Consequently, underwriting parties will be allocated 10.8 percent of the Rights Issue thus resulting in a fully subscribed Rights Issue and that Promore Pharma obtains SEK 48.6 million before issue costs.

Events after the reporting period

No major events were reported after the reporting period.

Financial information

Net sales and result second quarter 2021

The company has no revenues from products sales, therefore the Company's revenue amounted to MSEK 0.0 (0.0) in the period.

The company's costs for raw materials and consumables are mainly related to development costs, such as costs for clinical trials, patents, products for the clinical trials and consultants working with the development of the company's candidate drugs. In the quarter, these costs amounted to MSEK 5.1 (3.8). The increase is mainly explained by the fact that the company has started to invest in the investigational medicinal product etc. for the preparation of the PHSU05 clinical trial, and due to higher patent costs compared to last year.

Other external costs amounted to MSEK 1.6 (1.4), where the increase mainly is due to new reporting principles regarding remuneration to the board.

Personnel expenses costs were MSEK 1.1, which is unchanged from the same period last year.

The operating loss for the period amounted to MSEK -7.8, compared to MSEK -6.5 in 2020. Net loss for the period amounted to MSEK -7.9 (-6.4), corresponding to earnings per share of SEK -0.22 (-0.18).

Net sales and result first half year 2021

The company has no revenues from products sales, therefore the Company's revenue amounted to MSEK 0.0 (0.0) in the period.

The company's costs for raw materials and consumables are mainly related to development costs, such as costs for clinical trials, patents, products for the clinical trials and consultants working with the development of the company's candidate drugs. In the period, costs amounted to SEKM 8.9 (8.0), of which SEKM 2.0 is related to the closure of HEAL LL-37 during the first quarter.

Other external costs amounted to MSEK 3.7 (3.2), where the increase mainly is due to new reporting principles regarding remuneration to the board and higher advertising costs.

Personnel expenses costs were MSEK 2.3 compared to MSEK 2.2 in the same period previous year.

The operating loss for the period amounted to MSEK -14.9 compared to SEKM 14.0 last year. Net loss for the period amounted to MSEK -15.0 (-13.6), corresponding to earnings per share of SEK -0.41 (-0.37).

Liquidity and financing

The cash flow from operating activities during the first half year amounted to MSEK -60.9 (-21.0). The large negative number is due to the receivable of SEKM -48.6 related to the new issue which was booked in June. This is balanced in the cash flow analysis under Financing activities below.

The cash flow from investment activities amounted to SEKM +1.0 (+0.4), which is related to the sale of the final shares in Herantis Pharma Oyj.

The cash flow from financing activities was MSEK +48.7 (0.0) during the period, where the gross proceeds of SEKM 48.6 from the new issue is booked as a receivable.

The company's cash and cash equivalents amounted to MSEK 13.1 by 30 June 2021, compared to MSEK 18.6 by 31 March 2021, SEKM 24.2 by 31 December 2020 and MSEK 39.9 by 30 June 2020. The net proceeds of SEKM 45.0 from the new issue were transferred to the company in July 2021.

Auxiliary information

Number of shares

Promore Pharma's share is listed on Nasdaq First North (now Nasdaq First North Growth Market) in Stockholm since 6 July 2017 with the ticker PROMO and ISIN code SE0009947740. The number of shares during 2021 and 2020 was as follows:

	Apr-Jun		Jan-Jun	
Number of shares	2021	2020	2021	2020
Average number of shares	36 428 362	36 428 362	36 428 362	36 428 362
Number of shares by the end of the period	36 428 362	36 428 362	36 428 362	36 428 362

The main owners Midroc New Technology AB and PharmaResearch Products Ltd together owned approx. 58% of the shares in the company before the new issue.

Warrants – external partners

The company announced in March 2021 that, as a consequence of the changed priority for ensereptide, a total of 72,755 warrants in programs 3-7 issued in 2016 with a dilution effect of approximately 3.0% have been de-registered. After this, 54,599 warrants remain related to programs 1, 2 and 8, with a dilution effect of approximately 2.2%.

Warrants – LTI 2020

It was resolved at the Annual General Meeting in 2020 to adopt a performance-based stock savings program (LTI 2020) for certain employees and contractors in Promore Pharma. A maximum of 1,400,000 Performance Share Rights may be allotted under LTI 2020, corresponding to approximately 3.7 percent of the shares in the company. In accordance with the Board's proposal, the meeting resolved on a directed issue of 1,800,000 warrants with the right to subscribe for new shares in the company to implement LTI 2020. For those who are offered to join LTI 2020 and previously participated in the company's old bonus program, the old bonus agreements will be terminated without any awards.

Holding of shares in Herantis Pharma Oyj

The company has held shares in the Finnish biotech company Herantis Pharma Oyj. This is a consequence of a passive historic holding in the Finnish company Biocis Oy since the formation of Pergamum AB in 2010. Biocis has since then undergone a number of corporate mergers and ownership restructurings which has resulted in a holding of shares in Herantis Pharma Oyj, a company that executed an IPO in 2015. The last part of the shares were divested in Q1 2021.

Personnel

Promore Pharma has a small and cost-effective organization that is primarily focused on business development, project coordination as well as management of intellectual property and core development documentation. All personnel except the CEO operate on a consultancy basis. Per 30 June 2021, the company consequently had one employee.

Transactions with related parties

The company has not had any transactions with related parties during the period.

Accounting principles

The report has been drawn up in accordance with the Swedish Annual Accounts Act (1995:1554) and the Swedish Accounting Standards Board's (BFNAR) General Recommendation 2012:1: Annual Report and Consolidated Accounts ("K3").

Financial calendar

Interim report January – September 2021 23 November 2021

Review by auditor

This report has not been reviewed by the Company's auditor.

Solna 24 August 2021

Göran Pettersson

Ordförande

Marianne Dicander Alexandersson

Göran Linder

Kerstin Valinder Strinnholm

Satyendra Kumar

Hans-Peter Ostler

Consolidated income statement

Amounts in SEKk	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
Operating income					
Net sales	-	-	-	-	3
Other operating income	-1	-11	1	11	14
Operating expenses					
Commodities and supplies	-5 055	-3 845	-8 852	-7 987	-18 205
Other external expenses	-1 647	-1 416	-3 714	-3 160	-6 038
Personnel costs	-1 139	-1 068	-2 328	-2 224	-4 274
Depreciation and impairments on fixed assets	-	-304	-	-609	-609
Other operating expenses	-5	-7	-8	-29	-30
Operating loss (EBIT)	**-7 847**	**-6 651**	**-14 901**	**-13 998**	**-29 138**
Financial items					
Net financial items	-24	110	-65	442	-311
Profit/loss after financial items	**-7 872**	**-6 542**	**-14 966**	**-13 556**	**-29 449**
Profit/loss before tax	**-7 872**	**-6 542**	**-14 966**	**-13 556**	**-29 449**
Tax	-	-	-	-	-
Profit/Loss for the period	**-7 872**	**-6 542**	**-14 966**	**-13 556**	**-29 449**

Consolidated balance sheet

Amounts in SEKk	30 Jun 2021	2020	31 Dec 2020
ASSETS			
FIXED ASSETS			
Intangible fixed assets	-	-	-
Financial fixed assets	1	2 816	1 068
Total fixed assets	**1**	**2 816**	**1 068**
CURRENT ASSETS			
Current receivables	49 985	1 195	239
Accounts receivable		-	-
Other receivables	151	-	661
Cash and cash equivalents	13 086	39 944	24 249
Total current assets	**63 222**	**41 140**	**25 150**
TOTAL ASSETS	**63 223**	**43 955**	**26 217**
EQUITY AND LIABILITIES			
EQUITY			
Share capital	2 429	1 457	1 457
Other equity including the result for the period	53 965	37 181	21 332
Total equity	**56 394**	**38 638**	**22 789**
LONG-TERM LIABILITIES			
Liabilities to credit institutions	714	714	714
Other liabilities	237	341	107
Total long-term liabilities	**951**	**1 055**	**821**
CURRENT LIABILITIES			
Accounts payable	1 807	2 391	1 023
Deferred taxes	140		146
Other current liabilities	3 932	1 871	1 439
Total current liabilities	**5 879**	**4 262**	**2 608**
TOTAL EQUITY AND LIABILITIES	**63 223**	**43 955**	**26 217**

Consolidated cash flow analysis

Amounts in SEKk	Apr-Jun 2021	Apr-Jun 2020	Jan-Jun 2021	Jan-Jun 2020	Jan-Dec 2020
OPERATING ACTIVITIES					
Operating profit	-7 847	-6 651	-14 901	-13 998	-29 138
Adjustments for items not included in cash flow	-24	302	-27	597	592
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	**-7 872**	**-6 350**	**-14 928**	**-13 401**	**-28 547**
Increase/decrease other current receivables	-48 911	92	-49 236	3 578	3 873
Increase/decrease other current liabilities	2 700	235	3 271	-11 194	-12 804
Cash flow from operating activities	**-54 082**	**-6 023**	**-60 893**	**-21 017**	**-37 479**
INVESTING ACTIVITIES					
Sale of financial fixed assets	-	113	1 029	448	1 448
Cash flow from investing activities	**-**	**113**	**1 029**	**448**	**1 448**
FINANCING ACTIVITIES					
New share issue	48 571	-	48 571	-	-
Loans	-	-	130	-	-
Repaid loans	-	-29	-	-29	-264
Cash flow from financing activities	**48 571**	**-29**	**48 701**	**-29**	**-264**
Cash flow for the period	**-5 511**	**-5 939**	**-11 163**	**-20 599**	**-36 294**
Cash and cash equiv. at the beginning of the period	**18 597**	**45 884**	**24 249**	**60 543**	**60 543**
Exchange rate difference cash and cash equivalents	-	-	-	-	-
Cash and cash equiv. at the end of the period	**13 086**	**39 944**	**13 086**	**39 944**	**24 249**

Change in equity for the group

Amounts in SEKk	Share capital	Other paid-in capital	Other equity	Total equity
Amount at the beginning of the period (1 Jan 2021)	1 457	-	**21 332**	**22 789**
New share issue	972	-	47 599	48 571
Profit for the period	-	-	-14 966	-14 966
Amount at the end of the period (30 Jun 2021)	**2 429**	**-**	**53 965**	**56 394**
Amount at the beginning of the period (1 Jan 2020)	1 457	-	**50 737**	**52 194**
New share issue	-	-	-	-
Profit for the period	-	-	-7 014	-7 014
Amount at the end of the period (30 Jun 2020)	**1 457**	**-**	**43 723**	**45 180**

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

Email: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 56 52 45

Email: erik.magnusson@promorepharma.com

Street address: Fogdevreten 2, 171 65 Solna, Sweden

Website: www.promorepharma.com

Corporate registration number: 556639-6809

Promore Pharma's Certified Adviser is Erik Penser Bank AB .

Phone: [+46] 8 463 83 00

Email: certifiedadviser@penser.se